What is Cancer? Defining Cancer. National Cancer Institute, National Institutes of Health. 2014-03-07 [2014-12-05]. (原始内容存档于2014-06-25).
Pancreatic Cancer Treatment (PDQ®) Health Professional Version. National Cancer Institute. National Institutes of Health. 2014-02-21 [2014-11-24]. (原始内容存档于2014-10-22). "The highest cure rate occurs if the tumor is truly localized to the pancreas; however, this stage of disease accounts for less than 20% of cases. In cases with localized disease and small cancers (<2 cm) with no lymph node metastases and no extension beyond the capsule of the pancreas, complete surgical resection is associated with an actuarial five-year survival rate of 18% to 24%."
National Cancer Institute. Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®) Incidence and Mortality [2] (页面存档备份,存于互联网档案馆)
Cancer Facts & Figures 2010(PDF). American Cancer Society. 2010 [2014-12-05]. (原始内容(PDF)存档于2015-01-14). See p. 4 for incidence estimates, and p. 19 for survival percentages.
Cancer Facts and Figures 2014(PDF). American Cancer Society. [2015-01-05]. (原始内容存档(PDF)于2014-04-29)., p. 19, "Though evidence is still accumulating, consumption of red or processed meat, or meat cooked at very high temperatures, may slightly increase risk."
Cancer Facts and Figures 2014(PDF). American Cancer Society. [2015-01-05]. (原始内容存档(PDF)于2014-04-29)., Table, p. 18, rates adjusted for normal life expectancy
Pancreatic cancer statistics. Cancer Research UK. [2014-12-18]. (原始内容存档于2014-12-18).; "In 2010, in the UK, the lifetime risk of developing pancreatic cancer is 1 in 73 for men and 1 in 74 for women", noting "The lifetime risk ... has been calculated ... using the 'Current Probability' method; this is a different method used from most other cancer sites since the possibility of having more than one diagnosis of pancreatic cancer over the course of their lifetime is very low"
Chapter 15; Pancreas. Manual for Staging of Cancer(PDF) 2nd. American Joint Committee on Cancer. : 95–8 [2017-06-21]. (原始内容存档(PDF)于2014-11-29). See page 95 for citation regarding "... lesser degree of involvement of bones and brain and other anatomical sites."
Burns WR, Edil BH. Neuroendocrine pancreatic tumors: guidelines for management and update. Current treatment options in oncology. March 2012, 13 (1): 24–34. PMID 22198808. doi:10.1007/s11864-011-0172-2.
Lewis MA, Yao JC. Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Current Opinion in Endocrinology & Diabetes and Obesity. Feb 2014, 21 (1): 22–7. PMID 24310147. doi:10.1097/MED.0000000000000033.
Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012, 95 (2): 157–76. PMID 22262022. doi:10.1159/000335597.
Gulenchyn KY, Yao X, Asa SL, Singh S, Law C. Radionuclide therapy in neuroendocrine tumours: A systematic review. Clinical Oncology. 2012, 24 (4): 294–308. PMID 22221516. doi:10.1016/j.clon.2011.12.003.
Vinik AI. Advances in Diagnosis and Treatment of Pancreatic Neuroendocrine Tumors (PNETS). Endocrine Practice. 2014, 20 (11): 1–23. PMID 25297671. doi:10.4158/EP14373.RA.
Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, Krenning EP. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Seminars in Nuclear Medicine. 2010, 40 (2): 78–88. PMID 20113677. doi:10.1053/j.semnuclmed.2009.10.004.
Bodei L, Cremonesi M, Kidd M, Grana CM, Severi S, Modlin IM, Paganelli G. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors. Thoracic Surgery Clinics. 2014, 24 (3): 333–49. PMID 25065935. doi:10.1016/j.thorsurg.2014.04.005.
Castellano D, Grande E, Valle J, Capdevila J, Reidy-Lagunes D, O'Connor JM, Raymond E. Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. Cancer Chemotherapy and Pharmacology. 2014, 75 (6): 1099–114. PMID 25480314. doi:10.1007/s00280-014-2642-2.
Singh S, Dey C, Kennecke H, Kocha W, Maroun J, Metrakos P, Mukhtar T, Pasieka J, Rayson D, Rowsell C, Sideris L, Wong R, Law C. Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group. Annals of Surgical Oncology. 2014, 22 (8): 2685–99. PMID 25366583. doi:10.1245/s10434-014-4145-0.
About EUROPAC. European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC). University of Liverpool. [2014-07-17]. (原始内容存档于2014-07-26).
Neoptolemos, John P.; Abbruzzese, James; Urrutia, Raul A.; Büchler, Markus W. Pancreatic Cancer. Springer Science & Business Media. 2010-01-22: 288 [2017-06-21]. ISBN 978-0-387-77497-8. (原始内容存档于2022-10-19) (英语).
jhu.edu
pathology.jhu.edu
Types of Pancreas Tumors. The Sol Goldman Pancreas Cancer Research Center. Johns Hopkins Medicine. 2012 [2014-11-18]. (原始内容存档于2014-10-08).
Burns WR, Edil BH. Neuroendocrine pancreatic tumors: guidelines for management and update. Current treatment options in oncology. March 2012, 13 (1): 24–34. PMID 22198808. doi:10.1007/s11864-011-0172-2.
De La Cruz MS, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. Am Fam Physician. April 2014, 89 (8): 626–32. PMID 24784121.
Lewis MA, Yao JC. Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Current Opinion in Endocrinology & Diabetes and Obesity. Feb 2014, 21 (1): 22–7. PMID 24310147. doi:10.1097/MED.0000000000000033.
Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012, 95 (2): 157–76. PMID 22262022. doi:10.1159/000335597.
Gulenchyn KY, Yao X, Asa SL, Singh S, Law C. Radionuclide therapy in neuroendocrine tumours: A systematic review. Clinical Oncology. 2012, 24 (4): 294–308. PMID 22221516. doi:10.1016/j.clon.2011.12.003.
Vinik AI. Advances in Diagnosis and Treatment of Pancreatic Neuroendocrine Tumors (PNETS). Endocrine Practice. 2014, 20 (11): 1–23. PMID 25297671. doi:10.4158/EP14373.RA.
Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, Krenning EP. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Seminars in Nuclear Medicine. 2010, 40 (2): 78–88. PMID 20113677. doi:10.1053/j.semnuclmed.2009.10.004.
Bodei L, Cremonesi M, Kidd M, Grana CM, Severi S, Modlin IM, Paganelli G. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors. Thoracic Surgery Clinics. 2014, 24 (3): 333–49. PMID 25065935. doi:10.1016/j.thorsurg.2014.04.005.
Castellano D, Grande E, Valle J, Capdevila J, Reidy-Lagunes D, O'Connor JM, Raymond E. Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. Cancer Chemotherapy and Pharmacology. 2014, 75 (6): 1099–114. PMID 25480314. doi:10.1007/s00280-014-2642-2.
Singh S, Dey C, Kennecke H, Kocha W, Maroun J, Metrakos P, Mukhtar T, Pasieka J, Rayson D, Rowsell C, Sideris L, Wong R, Law C. Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group. Annals of Surgical Oncology. 2014, 22 (8): 2685–99. PMID 25366583. doi:10.1245/s10434-014-4145-0.
Cancer Facts & Figures 2010(PDF). American Cancer Society. 2010 [2014-12-05]. (原始内容(PDF)存档于2015-01-14). See p. 4 for incidence estimates, and p. 19 for survival percentages.
Pancreatic Cancer Treatment (PDQ®) Health Professional Version. National Cancer Institute. National Institutes of Health. 2014-02-21 [2014-11-24]. (原始内容存档于2014-10-22). "The highest cure rate occurs if the tumor is truly localized to the pancreas; however, this stage of disease accounts for less than 20% of cases. In cases with localized disease and small cancers (<2 cm) with no lymph node metastases and no extension beyond the capsule of the pancreas, complete surgical resection is associated with an actuarial five-year survival rate of 18% to 24%."
Neoptolemos, John P.; Abbruzzese, James; Urrutia, Raul A.; Büchler, Markus W. Pancreatic Cancer. Springer Science & Business Media. 2010-01-22: 288 [2017-06-21]. ISBN 978-0-387-77497-8. (原始内容存档于2022-10-19) (英语).
Types of Pancreas Tumors. The Sol Goldman Pancreas Cancer Research Center. Johns Hopkins Medicine. 2012 [2014-11-18]. (原始内容存档于2014-10-08).
Chapter 15; Pancreas. Manual for Staging of Cancer(PDF) 2nd. American Joint Committee on Cancer. : 95–8 [2017-06-21]. (原始内容存档(PDF)于2014-11-29). See page 95 for citation regarding "... lesser degree of involvement of bones and brain and other anatomical sites."
Cancer Facts and Figures 2014(PDF). American Cancer Society. [2015-01-05]. (原始内容存档(PDF)于2014-04-29)., p. 19, "Though evidence is still accumulating, consumption of red or processed meat, or meat cooked at very high temperatures, may slightly increase risk."
Cancer Facts and Figures 2014(PDF). American Cancer Society. [2015-01-05]. (原始内容存档(PDF)于2014-04-29)., Table, p. 18, rates adjusted for normal life expectancy
Pancreatic cancer statistics. Cancer Research UK. [2014-12-18]. (原始内容存档于2014-12-18).; "In 2010, in the UK, the lifetime risk of developing pancreatic cancer is 1 in 73 for men and 1 in 74 for women", noting "The lifetime risk ... has been calculated ... using the 'Current Probability' method; this is a different method used from most other cancer sites since the possibility of having more than one diagnosis of pancreatic cancer over the course of their lifetime is very low"
About EUROPAC. European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC). University of Liverpool. [2014-07-17]. (原始内容存档于2014-07-26).